JP Morgan Chase’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-80,627
| Closed | -$330K | – | 7199 |
|
|
2022
Q1 | $330K | Sell |
80,627
-40,027
| -33% | -$145K | ﹤0.01% | 4932 |
|
|
2021
Q4 | $431K | Buy |
120,654
+27,557
| +30% | +$96.4K | ﹤0.01% | 4933 |
|
|
2021
Q3 | $339K | Sell |
93,097
-156,670
| -63% | -$633K | ﹤0.01% | 4946 |
|
|
2021
Q2 | $1.09M | Buy |
249,767
+79,970
| +47% | +$326K | ﹤0.01% | 4232 |
|
|
2021
Q1 | $697K | Buy |
169,797
+52,092
| +44% | +$226K | ﹤0.01% | 4472 |
|
|
2020
Q4 | $469K | Sell |
117,705
-651,395
| -85% | -$2.11M | ﹤0.01% | 4406 |
|
|
2020
Q3 | $2.08M | Sell |
769,100
-65,652
| -8% | -$182K | ﹤0.01% | 3198 |
|
|
2020
Q2 | $2.3M | Buy |
834,752
+308,354
| +59% | +$860K | ﹤0.01% | 3020 |
|
|
2020
Q1 | $1.24M | Buy |
526,398
+470,246
| +837% | +$1.6M | ﹤0.01% | 3275 |
|
|
2019
Q4 | $264K | Buy |
56,152
+3,128
| +6% | +$12.8K | ﹤0.01% | 4566 |
|
|
2019
Q3 | $177K | Buy |
53,024
+8,600
| +19% | +$28.3K | ﹤0.01% | 4687 |
|
|
2019
Q2 | $141K | Buy |
44,424
+9,203
| +26% | +$26.6K | ﹤0.01% | 4801 |
|
|
2019
Q1 | $107K | Sell |
35,221
-1,656
| -4% | -$5.37K | ﹤0.01% | 4861 |
|
|
2018
Q4 | $100K | Sell |
36,877
-904,240
| -96% | -$2.98M | ﹤0.01% | 4852 |
|
|
2018
Q3 | $3.16M | Buy |
941,117
+497,523
| +112% | +$1.54M | ﹤0.01% | 3116 |
|
|
2018
Q2 | $1.15M | Sell |
443,594
-5,040
| -1% | -$12.5K | ﹤0.01% | 3752 |
|
|
2018
Q1 | $987K | Buy |
448,634
+377,824
| +534% | +$850K | ﹤0.01% | 3679 |
|
|
2017
Q4 | $141K | Buy |
+70,810
| New | +$154K | ﹤0.01% | 4540 |
|
|
2017
Q3 | – | Sell |
-127,438
| Closed | -$410K | – | 5277 |
|
|
2017
Q2 | $410K | Buy |
127,438
+93,538
| +276% | +$265K | ﹤0.01% | 3800 |
|
|
2017
Q1 | $96K | Buy |
+33,900
| New | +$81.5K | ﹤0.01% | 4341 |
|
|
2016
Q4 | – | Sell |
-8,992
| Closed | -$15K | – | 5198 |
|
|
2016
Q3 | $15K | Buy |
8,992
+3,802
| +73% | +$4.66K | ﹤0.01% | 4244 |
|
|
2016
Q2 | $5K | Buy |
+5,190
| New | +$5.01K | ﹤0.01% | 4467 |
|
|
2015
Q3 | – | Sell |
-844,100
| Closed | -$1.76M | – | 4147 |
|
|
2015
Q2 | $1.76M | Buy |
+844,100
| New | +$2.05M | ﹤0.01% | 2978 |
|
|
2013
Q4 | – | Sell |
-24,659
| Closed | -$100K | – | 4293 |
|
|
2013
Q3 | $100K | Sell |
24,659
-16,894
| -41% | -$73.8K | ﹤0.01% | 4177 |
|
|
2013
Q2 | $173K | Buy |
+41,553
| New | +$161K | ﹤0.01% | 4025 |
|
Other funds holding ATRS
JP Morgan Chase's ATRS Position: Q2 2022 in Review
JP Morgan Chase sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 80,627 shares — an estimated $330K sold.
JP Morgan Chase first reported a position in ATRS in Q2 2013 and held it in 25 quarters. The position peaked at $3.16M in Q3 2018. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- JP Morgan Chase reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- JP Morgan Chase sold 80,627 Antares Pharma, Inc. shares in Q2 2022, an estimated $330K.
- JP Morgan Chase first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 25 quarters.
- JP Morgan Chase's Antares Pharma, Inc. position peaked at $3.16M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.